



**Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022**

April 4, 2022

**Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemodialysis**

STAMFORD, Conn., April 04, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing hemodialysis will be presented in a poster at the National Kidney Foundation Spring Clinical Meetings 2022 (SCM22), to be held April 6-10, 2022, in Boston, MA.

Details for the poster presentation are as follows:

**Title:** Reduction of Pruritus by Difelikefalin Correlates With Reductions in Markers for Pruritus and Inflammation in Subjects Undergoing Hemodialysis

**Poster Number:** 207

**Date and Time:** April 7, 2022, 6:00-7:30 p.m. ET

**Presenter:** Shayan Shirazian, MD, Columbia University College of Physicians and Surgeons, New York, NY

The ePoster is available at: <https://www.kidney.org/spring-clinical>.

In addition, details for other posters highlighting KORSUVA injection are as follows:

**Title:** Effect of Treatment with Difelikefalin on Itch Severity in Patients with Chronic Kidney Disease-Associated Pruritus Measured by the Patient Global Impression of Change

**Poster Number:** 212

**Title:** Improvement in Itch-Related Sleep Disruption with Difelikefalin in Patients with Moderate to Severe Chronic Kidney Disease Associated Pruritus Undergoing Hemodialysis: A Post-hoc Analysis of an Open-Label, Multicenter Study

**Poster Number:** 261

**Title:** CKD-associated Pruritus After 12 Weeks of Therapy with Difelikefalin Among Hemodialysis Patients with Severe Pruritus: A Post-hoc Analysis of Phase 3 Studies

**Poster Number:** 262

**About Cara Therapeutics**

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company's novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com) and follow the company on [Twitter](#), [LinkedIn](#) and [Instagram](#).

**MEDIA CONTACT:**

Annie Spinetta

6 Degrees

973-768-2170

[aspinetta@6degreespr.com](mailto:aspinetta@6degreespr.com)

**INVESTOR CONTACT:**

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

[investor@caratherapeutics.com](mailto:investor@caratherapeutics.com)



Source: Cara Therapeutics, Inc.